Third Quarter 2025 Financial Results Welcome and Participants Dr. Jeffrey Graves President & Chief Executive Officer Phyllis Nordstrom Executive Vice President & Interim Chief Financial Officer Monica Gould November 5, 2025 Investor Relations 2 Forward Looking Statements Certain statements made in this presentation that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involv ...

Financial Performance - Q2 2025 consolidated revenue was $95 million, reflecting an 8% QoQ rebound excluding Geomagic[29] - Medical Technologies revenue grew 13% YoY and 16% QoQ, representing over $80 million of FY'24 revenues[19] - The company achieved significant OpEx reductions of $17 million YoY and $15 million QoQ[35] - Net income for Q2 2025 was $1044 million, with GAAP EPS at $057[39] - The company expects to exit Q4'25 with operating expenses in the low $40 million range[13] Strategic Initiatives - The company completed the sale of the Geomagic business for nearly $120 million in cash on April 1, 2025[10, 44] - A debt transaction in June permanently retired $88 million in debt and refinanced $92 million through 2030, along with repurchasing 8 million common shares[10, 44] - Cost reduction and profitability improvement initiatives target over $85 million of annualized savings planned through 1H'26[12] Balance Sheet - The company ended the quarter with approximately $134 million in cash, cash equivalents, and restricted cash[44] - As of August 2025, the company's global cash, cash equivalents, and restricted cash amounted to approximately $130 million[44]

Financial Performance - The company's Q4 2024 consolidated revenue was $111 million, a decrease of approximately 3% year-over-year (YoY) compared to $115 million in Q4 2023[30, 31] - Full year 2024 consolidated revenue was $440 million, a decrease of approximately 10% YoY compared to $488 million in FY 2023[32, 33] - Healthcare Solutions (HSG) revenue in Q4 2024 was $40 million, a decrease of approximately 21% YoY compared to $51 million in Q4 2023[30, 31] - Healthcare Solutions (HSG) full year 2024 revenue was $190 million, a decrease of approximately 11% YoY compared to $213 million in FY 2023[32, 33] - Industrial Solutions (ISG) revenue in Q4 2024 was $71 million, an increase of approximately 11% YoY compared to $64 million in Q4 2023[30, 31] - Industrial Solutions (ISG) full year 2024 revenue was $250 million, a decrease of approximately 9% YoY compared to $275 million in FY 2023[32, 33] - The company's Non-GAAP Adjusted EBITDA for FY 2024 was a loss of $66.4 million, compared to a loss of $26.3 million in FY 2023[40, 62] - The company's Non-GAAP diluted loss per share for FY 2024 was $0.62, compared to a loss of $0.28 in FY 2023[40, 65] Strategic Initiatives and Outlook - The company expects to achieve over $50 million of annualized savings from Gross Margin (GM) and Operating Expense (OpEx) improvements over the next 6 quarters[9, 24] - The company anticipates revenues for FY 2025, normalized for divestiture, to range from essentially flat to modest growth[26, 47] - The company is targeting to exit 2025 with positive Adjusted EBITDA[26] - The company expects Non-GAAP operating expenses to be between $200 million and $220 million for FY 2025[47]